Fill out the form below to download your copy.
Launched just over a decade ago, Next Generation Sequencing (NGS)* has transformed the genomics and molecular diagnostics landscape. This technology is used for applications including human whole genome sequencing (WGS), whole exome sequencing (WES; 1-2% of the genome that encodes proteins), targeted sequencing using panels of a few to thousands of genes, and expression profiling (i.e., RNA-Seq). We forecast that the manufacturer market size will reach $3.2B in 2017, and grow at 12% p.a. to $4.6B in 2020, driven primarily by adoption from clinical customers worldwide**. NGS is poised to revolutionize not only medical research in academic laboratories and Biopharma, but also the health care landscape and applied markets (e.g., AgBio, food testing).